ISSN: 1859 - 2872
Effectiveness of intensity-modulated radiation therapy (IMRT) combined androgen deprivation therapy (ADT) for prostate cancer stage II-IVa at Cho Ray Cancer Center
Main Article Content
Keywords
Abstract
Objective: To evaluate the effectiveness of intensity-modulated radiation therapy (IMRT) combined androgen deprivation therapy (ADT) for prostate cancer stage II-IVs at Cho Ray Cancer Center. Subject and method: Prospective, case series report of 88 prostate cancer stage II-IVa patients, treated with Intensity- Modulated Radiation Therapy (IMRT) with cone-beam computerized tomography imaging-guided combined androgen deprivation therapy (ADT) from June 01, 2015 to December 31, 2021 at Cho Ray Cancer Center. Result: 88 patients enrolled with median age of 71 (range of 51-91). The prescribed radiation dose ranged from 72Gy to 78Gy. Median percentage of planning target volumes received 95% dose was good (97%-99%). All organs at risk received acceptable doses. Preradiation median PSA was 38ng/ml. Post-radiation median PSA was 0.175ng/ml (p=0.023). Progresssion-free survival at 2-year, 3-year, 5-year were 93.5%, 89.3%, 78.5%, respectively. Conclusion: IMRT combined androgen deprivation therapy (ADT) for prostate cancer stage II-IVa is safe technique and improves survival rate of patients.
Article Details
References
2. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Phys 53(5): 1097-1105.
3. Baum C, Alber M, Birkner M et al (2006) Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiother Oncol 78: 27-35.
4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300.
5. Fabio LC, Daniel H, Mack R et al (2013) Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on radiation therapy oncology group study 9413. Cancer 1999-2004.
6. Fenoglietto P, Laliberte B, Allaw A et al (2008) Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in Prostate Cancer patients with significant variation of clinical target volume and/or organ at risk. Radiotherapy and Oncology. 88: 77-87.
7. Hakmin Lee, Minseung Lee, Seok-Soo Byun, Sang Eun Lee, Sung Kyu Hong (2018) Evaluation of Prostate Cancer Stage Groups Updated in the 8th Edition of the American Joint Committee on Cancer TumoreNodeeMetastasis Staging Manual. Clinical Genitourinary Cancer: 1-6.
8. Mottet N, Peneau M, Mazeron J.J, Molinie V, Richaud P (2012) Addition of Radiotherapy to long-term Androgen Deprivation in locally advanced prostate cancer: An open randomised phase 3 trial. European Urology 62: 213-219.
9. Roach M, DeSilvio M, Lawton C et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904-1911.
10. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3): 209-249.
Article Sidebar
